Mulder Lab (Nanomedicine)
The Nanomedicine Laboratory (Nano-TMII) resides within the Translational and Molecular Imaging Institute at the Icahn School of Medicine at Mount Sinai.
Nano-TMII's mission is to develop and advance nanomedicinal approaches to allow a better understanding, identification and treatment of the most detrimental pathologies today: cardiovascular disease and cancer. The research projects range from fundamental, including nanotechnologies to better understand lipoprotein biology, to translational, with one of the developed nanotherapies being in clinical trials: http://clinicaltrials.gov/show/NCT01601106
Nano-TMII is directed by Dr. Willem Mulder. He is an Associate Professor at the Icahn School of Medicine at Mount Sinai and a Professor of Cardiovascular Nanomedicine at the Academic Medical Center of the University of Amsterdam. Nano-TMII's research is funded by the National Heart Lung and Blood Institute, the National Cancer Institute and NHLBI’s Program of Excellence in Nanotechnology as well as the Dutch Science Foundation (NWO).TMII - Nanomedicine Program